Eight years of the East African Community Medicines Regulatory Harmonization initiative: Implementation, progress, and lessons learned.


Journal

PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360

Informations de publication

Date de publication:
08 2020
Historique:
entrez: 14 8 2020
pubmed: 14 8 2020
medline: 25 9 2020
Statut: epublish

Résumé

Jane H. Mashingia and colleagues reveal the progress made to date for the East African Community Medicines Regulatory Harmonization initiative.

Identifiants

pubmed: 32785219
doi: 10.1371/journal.pmed.1003134
pii: PMEDICINE-D-19-03915
pmc: PMC7423058
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1003134

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Déclaration de conflit d'intérêts

I have read the journal’s policy and the authors of this manuscript have the following competing interests: DH, DM, & ML declare they are employees of the Bill & Melinda Gates Foundation, which funds the EAC MRH initiative.

Références

PLoS One. 2019 Jun 19;14(6):e0218617
pubmed: 31216323

Auteurs

Jane H Mashingia (JH)

East African Community Secretariat, Arusha, Tanzania.

Vincent Ahonkhai (V)

Gwynedd Consultancy, LLC, Philadelphia, Pennsylvania, United States of America.

Noel Aineplan (N)

National Drug Authority, Kampala, Uganda.

Aggrey Ambali (A)

African Union Development Agency-New Partnership for Africa's Development, Midrand, South Africa.

Apollo Angole (A)

National Drug Authority, Kampala, Uganda.

Mawien Arik (M)

Drug and Food Control Authority, Juba, South Sudan.

Samvel Azatyan (S)

World Health Organization, Geneva, Switzerland.

Peter Baak (P)

Drug and Food Control Authority, Juba, South Sudan.

Emmanuel Bamenyekanye (E)

Directorate of Pharmacy, Medicines, and Laboratories, Bujumbura, Burundi.

Aimable Bizoza (A)

Rwanda Food & Drugs Authority, Kigali, Rwanda.

Chimwemwe Chamdimba (C)

African Union Development Agency-New Partnership for Africa's Development, Midrand, South Africa.

Petra Doerr (P)

Petra Doerr Consulting Ltd., Herznach, Switzerland.

Adam Fimbo (A)

Tanzania Medicines and Medical Devices Authority, Dar Es Salaam, Tanzania.

Alex Gisagara (A)

Rwanda Food & Drugs Authority, Kigali, Rwanda.

Hidaya Hamad (H)

Zanzibar Food & Drug Agency, Zanzibar City, Zanzibar.

Rachelle Harris (R)

Harris Access Consulting Ltd, London, United Kingdom.

Dan Hartman (D)

Bill & Melinda Gates Foundation, Seattle, Washington, United States of America.

Joseph Kabatende (J)

Rwanda Food & Drugs Authority, Kigali, Rwanda.

Charles Karangwa (C)

Rwanda Food & Drugs Authority, Kigali, Rwanda.

Agnes Sitta Kijo (AS)

Tanzania Medicines and Medical Devices Authority, Dar Es Salaam, Tanzania.

Murray Lumpkin (M)

Bill & Melinda Gates Foundation, Seattle, Washington, United States of America.

Shani Maboko (S)

Tanzania Medicines and Medical Devices Authority, Dar Es Salaam, Tanzania.

David Matle (D)

Tanzania Medicines and Medical Devices Authority, Dar Es Salaam, Tanzania.

Apollo Muhairwe (A)

World Bank, Washington DC, United States of America.

John Patrick Mwesigye (JP)

East African Community Secretariat, Arusha, Tanzania.

Bonaventure Nyabenda (B)

Directorate of Pharmacy, Medicines, and Laboratories, Bujumbura, Burundi.

Alexander Schulze (A)

Swiss Agency for Development and Cooperation, Bern, Switzerland.

Andreas Seiter (A)

World Bank, Washington DC, United States of America.

Gordon Sematiko (G)

National Drug Authority, Kampala, Uganda.

Margareth Sigonda (M)

African Union Development Agency-New Partnership for Africa's Development, Midrand, South Africa.

Hiiti Sillo (H)

World Health Organization, Geneva, Switzerland.

Burhani Simai (B)

Zanzibar Food & Drug Agency, Zanzibar City, Zanzibar.

Fred Siyoi (F)

Pharmacy & Poisons Board, Nairobi, Kenya.

Stanley Sonoiya (S)

East African Community Secretariat, Arusha, Tanzania.

Paul Tanui (P)

African Union Development Agency-New Partnership for Africa's Development, Midrand, South Africa.

Mike Ward (M)

World Health Organization, Geneva, Switzerland.

Felistas Yano (F)

Pharmacy & Poisons Board, Nairobi, Kenya.

David Mukanga (D)

Bill & Melinda Gates Foundation, Seattle, Washington, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH